文献速递肿瘤 PET/CT神经核医学

使用68Ga-NODAGA-Exendin-4 PET/CT改善胰岛素瘤的定位

Improved Localization of Insulinomas Using 68Ga-NODAGA-Exendin-4 PET/CT.
PubMed 文献 · J Nucl Med · 2024-12-03

这项前瞻性多中心研究纳入69例生化证实的成人内源性高胰岛素性低血糖患者,比较68Ga-NODAGA-exendin-4 PET/CT与所有常规影像对胰岛素瘤定位的诊断准确性。结果显示exendin PET/CT临床判读准确率94.4%,高于DOTA-SSA PET/CT的64.8%、增强CT/增强弥散加权成像-MRI的83.3%和超声内镜的82.8%。

要点

  • exendin PET/CT临床判读准确率94.4%(95% CI,84.6%-98.8%),高于常规影像。
  • 13%的患者仅在exendin PET/CT后才获得正确诊断。
  • exendin PET/CT的胰岛素瘤与背景比值和对比噪声比均高于DOTA-SSA PET/CT。

核心结论

  • 本研究在唯一的前瞻性比较中证明exendin PET/CT对良性胰岛素瘤术前定位优于所有当前常规影像方法,提供了临床实施所需的证据水平。

研究设计与样本

  • 前瞻性多中心研究,纳入69例生化证实的成人内源性高胰岛素性低血糖患者,均接受exendin PET/CT和当前常规影像检查。
  • 图像经临床判读和专家判读评估,图像质量通过定量分析确定。

主要发现

  • 基于临床判读,exendin PET/CT准确率为94.4%(95% CI,84.6%-98.8%),高于DOTA-SSA PET/CT的64.8%(95% CI,50.6%-77.3%)、增强CT/增强弥散加权成像-MRI的83.3%(95% CI,70.7%-92.1%)和超声内镜的82.8%(95% CI,64.1%-94.1%)。
  • 13%的患者仅在exendin PET/CT后才获得正确诊断。
  • exendin PET/CT的判读者间一致性高于DOTA-SSA PET/CT和增强CT/增强弥散加权成像-MRI(Cohen κ,1.0 vs. 0.5和0.55)。
  • exendin PET/CT的胰岛素瘤与背景比值高于DOTA-SSA PET/CT(15.3 ± 6.7 vs. 5.2 ± 3.0),对比噪声比也高于DOTA-SSA PET/CT(22.6 ± 11.1 vs. 5.1 ± 3.7)。

关键数值与推荐

  • exendin PET/CT临床判读准确率94.4%(95% CI,84.6%-98.8%),DOTA-SSA PET/CT为64.8%(95% CI,50.6%-77.3%)。
  • 增强CT/增强弥散加权成像-MRI准确率83.3%(95% CI,70.7%-92.1%),超声内镜为82.8%(95% CI,64.1%-94.1%)。
  • exendin PET/CT与DOTA-SSA PET/CT的判读者间一致性Cohen κ分别为1.0和0.5,增强CT/增强弥散加权成像-MRI为0.55。
  • exendin PET/CT的胰岛素瘤与背景比值为15.3 ± 6.7,DOTA-SSA PET/CT为5.2 ± 3.0。
  • exendin PET/CT的对比噪声比为22.6 ± 11.1,DOTA-SSA PET/CT为5.1 ± 3.7。

临床怎么用

  • 原文结论指出exendin PET/CT对良性胰岛素瘤术前定位优于所有当前常规影像方法,提供了临床实施所需的证据水平。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Precise anatomic localization of insulinomas is crucial for surgical treatment. Current routine noninvasive imaging techniques, including CT, MRI, and 68Ga-DOTA-somatostatin analog (DOTA-SSA) PET/CT, have limited sensitivity. Endoscopic ultrasound is highly sensitive but invasive. In this prospective multicenter study, we compared the diagnostic accuracy of 68Ga-NODAGA-exendin-4 (exendin) PET/CT with all routine imaging procedures for the localization of insulinomas. Methods: Sixty-nine adults with biochemically proven adult endogenous hyperinsulinemic hypoglycemia underwent exendin PET/CT and current routine imaging. Images were evaluated in a clinical reading and in an expert reading. Image quality was determined by quantitative analysis. Results: Based on clinical readings, the accuracy of exendin PET/CT (94.4%; 95% CI, 84.6%-98.8%) was greater than that of DOTA-SSA PET/CT (64.8%; 95% CI, 50.6%-77.3%), contrast-enhanced CT/contrast-enhanced diffusion-weighted imaging-MRI (83.3%; 95% CI, 70.7%-92.1%), and endoscopic ultrasound (82.8%; 95% CI, 64.1%-94.1%). In 13% of patients, a correct diagnosis was only reached after exendin PET/CT. Interobserver agreement between readings was higher for exendin PET/CT than for DOTA-SSA PET/CT and contrast-enhanced CT/contrast-enhanced diffusion-weighted imaging-MRI (Cohen κ, 1.0 vs. 0.5 and 0.55). Exendin PET/CT provided a higher insulinoma-to-background ratio (15.3 ± 6.7 vs. 5.2 ± 3.0) and contrast-to-noise ratio (22.6 ± 11.1 vs. 5.1 ± 3.7) than did DOTA-SSA PET/CT. Conclusion: This study demonstrates the superiority of exendin PET/CT in a unique prospective comparison to all current routine imaging modalities for preoperative localization of benign insulinomas, providing the level of evidence needed for clinical implementation.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Boss M, Eriksson O, Mikkola K, et al. Improved Localization of Insulinomas Using 68Ga-NODAGA-Exendin-4 PET/CT. J Nucl Med. 2024. PMID: 39419553. doi:10.2967/jnumed.124.268158

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。